Under the terms of the agreement, PerkinElmer will acquire Pediatrix’s metabolic screening laboratory and its StepOne newborn screening product that is capable of analyzing more than 50 inherited disorders in newborns. Currently, Pediatrix’s screening laboratory provides neonatal screening and consultative services to hospitals, medical groups, and the states of Maryland, Mississippi, Louisiana, Nebraska and Pennsylvania, as well as the District of Columbia.
Gregory Summe, chairman and CEO of PerkinElmer, said: “This announcement builds on our strategy to expand the capabilities of our Genetic Screening business to protect the health of mothers and babies from pregnancy to birth and beyond. The company recently completed the acquisition of ViaCell, providing it with ViaCord, a leading cord blood preservation service. PerkinElmer is building an enhanced capability to deliver a growing portfolio of world-class neonatal and prenatal/maternal health solutions to consumers through their healthcare professionals.”